PDIA5 and glioblastoma: Therefore, targeting PDIA5 through other biomedical engineering approaches, such as siRNA, antibodies, or specific gene-engineered drug delivery methods, may be more effective at this stage and could be very promising for the clinical therapy of patients with GBM.